CN115210263A - 抗axl抗体和组合物 - Google Patents

抗axl抗体和组合物 Download PDF

Info

Publication number
CN115210263A
CN115210263A CN202180017213.3A CN202180017213A CN115210263A CN 115210263 A CN115210263 A CN 115210263A CN 202180017213 A CN202180017213 A CN 202180017213A CN 115210263 A CN115210263 A CN 115210263A
Authority
CN
China
Prior art keywords
amino acid
seq
antibody
nos
axl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180017213.3A
Other languages
English (en)
Chinese (zh)
Inventor
T·吉廷
T·林德斯泰德
A·威勒
A·沃索
E·M·C·梅兰德
J·S·雅各布森
R·W·汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of CN115210263A publication Critical patent/CN115210263A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180017213.3A 2020-02-28 2021-02-26 抗axl抗体和组合物 Pending CN115210263A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062982852P 2020-02-28 2020-02-28
US62/982,852 2020-02-28
PCT/IB2021/051636 WO2021171257A1 (en) 2020-02-28 2021-02-26 Anti-axl antibodies and compositions

Publications (1)

Publication Number Publication Date
CN115210263A true CN115210263A (zh) 2022-10-18

Family

ID=75426640

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180017213.3A Pending CN115210263A (zh) 2020-02-28 2021-02-26 抗axl抗体和组合物

Country Status (17)

Country Link
US (1) US11807688B2 (https=)
EP (1) EP4110824A1 (https=)
JP (1) JP7748377B2 (https=)
KR (1) KR20220148237A (https=)
CN (1) CN115210263A (https=)
AR (1) AR121441A1 (https=)
AU (1) AU2021225490B2 (https=)
BR (1) BR112022015977A2 (https=)
CA (1) CA3170975A1 (https=)
CL (1) CL2022002259A1 (https=)
CO (1) CO2022012159A2 (https=)
IL (1) IL295596A (https=)
MX (1) MX2022010670A (https=)
MY (1) MY209381A (https=)
PE (1) PE20221783A1 (https=)
PH (1) PH12022552041A1 (https=)
WO (1) WO2021171257A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119591720A (zh) * 2024-11-28 2025-03-11 北京大学深圳研究生院 抗人axl抗体、基因及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026001894A1 (zh) * 2024-06-24 2026-01-02 上海医药集团生物治疗技术有限公司 靶向axl的嵌合抗原受体及其用途
CN119912586B (zh) * 2024-12-31 2025-09-30 四川省肿瘤医院 基于受体酪氨酸激酶家族axl改造的嵌合抗原受体及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102421802A (zh) * 2009-05-11 2012-04-18 U3制药有限公司 人源化的axl抗体
CN104755500A (zh) * 2012-11-08 2015-07-01 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹的HER3抗原结合蛋白
WO2017009258A1 (en) * 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
CN106573979A (zh) * 2014-06-18 2017-04-19 卑尔根生物股份公司 抗axl抗体
WO2017220695A1 (en) * 2016-06-22 2017-12-28 Bergen Teknologioverføring As Anti-axl antagonistic antibodies
CN108290953A (zh) * 2015-10-02 2018-07-17 西福根有限公司 抗pd-1抗体和组合物
WO2019197506A1 (en) * 2018-04-10 2019-10-17 Genmab A/S Axl-specific antibodies for cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CA2706549A1 (en) * 2007-11-15 2009-05-22 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
BR112012027995A2 (pt) * 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
JP6931609B2 (ja) 2014-12-18 2021-09-08 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Ａｘｌアンタゴニスト抗体
TN2018000333A1 (en) * 2016-04-12 2020-01-16 Symphogen As Anti-tim-3 antibodies and compositions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102421802A (zh) * 2009-05-11 2012-04-18 U3制药有限公司 人源化的axl抗体
CN104755500A (zh) * 2012-11-08 2015-07-01 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹的HER3抗原结合蛋白
CN106573979A (zh) * 2014-06-18 2017-04-19 卑尔根生物股份公司 抗axl抗体
WO2017009258A1 (en) * 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
CN108290953A (zh) * 2015-10-02 2018-07-17 西福根有限公司 抗pd-1抗体和组合物
WO2017220695A1 (en) * 2016-06-22 2017-12-28 Bergen Teknologioverføring As Anti-axl antagonistic antibodies
WO2019197506A1 (en) * 2018-04-10 2019-10-17 Genmab A/S Axl-specific antibodies for cancer treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119591720A (zh) * 2024-11-28 2025-03-11 北京大学深圳研究生院 抗人axl抗体、基因及其应用

Also Published As

Publication number Publication date
PH12022552041A1 (en) 2023-11-29
BR112022015977A2 (pt) 2022-10-11
PE20221783A1 (es) 2022-11-16
WO2021171257A1 (en) 2021-09-02
EP4110824A1 (en) 2023-01-04
MX2022010670A (es) 2022-09-23
KR20220148237A (ko) 2022-11-04
AR121441A1 (es) 2022-06-08
IL295596A (en) 2022-10-01
AU2021225490B2 (en) 2025-11-27
CA3170975A1 (en) 2021-09-02
US11807688B2 (en) 2023-11-07
JP7748377B2 (ja) 2025-10-02
CL2022002259A1 (es) 2023-04-14
TW202146455A (zh) 2021-12-16
JP2023515821A (ja) 2023-04-14
CO2022012159A2 (es) 2022-10-31
AU2021225490A1 (en) 2022-09-15
US20210269532A1 (en) 2021-09-02
MY209381A (en) 2025-07-04

Similar Documents

Publication Publication Date Title
CN115023439B (zh) 抗cd73抗体
EP3368572B1 (en) Anti-pd-1 antibodies and compositions
JP7679399B2 (ja) 抗ｆｌｔ３抗体及び組成物
TW202313683A (zh) 抗nkg2a抗體及組合物
JP7748377B2 (ja) 抗ａｘｌ抗体及び組成物
RU2837590C1 (ru) Антитела против axl и композиции
RU2837590C9 (ru) Антитела против axl и композиции
HK40081002A (en) Anti-axl antibodies and compositions
TWI920062B (zh) 抗axl抗體及組合物
RU2836004C1 (ru) Антитела и композиции против flt3
HK40084729A (en) Anti-flt3 antibodies and compositions
CA3000564C (en) Anti-pd-1 antibodies and compositions
EA052808B1 (ru) Антитела и композиции против flt3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230406

Address after: Inside the French Pavilion

Applicant after: LES LABORATOIRES SERVIER

Address before: Rupp, Denmark

Applicant before: SYMPHOGEN A/S

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081002

Country of ref document: HK